Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles

Bhaskar Venkata Kameswara Subrahmanya Lakkakula, Batoul Farran, Saikrishna Lakkakula, Sujatha Peela, Nagendra Sastry Yarla, Pallaval Veera Bramhachari, Mohammad Amjad Kamal, Madhu Sudhana Saddala, Ganji Purnachandra Nagaraju

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Pancreatic cancer (PC) is an aggressive carcinoma and the fourth cause of cancer deaths in Western countries. Although surgery is the most effective therapeutic option for PC, the management of unresectable, locally advanced disease is highly challenging. Our improved understanding of pancreatic tumor biology and associated pathways has led to the development of various treatment modalities that can control the metastatic spread of PC. This review intends to present trials of small molecule tyrosine kinase inhibitors (TKIs) in PC management and the troubles encountered due to inevitable acquired resistance to TKIs.

Original languageEnglish (US)
Pages (from-to)149-167
Number of pages19
JournalSeminars in Cancer Biology
StatePublished - Jun 2019
Externally publishedYes


  • Clinical trials
  • Pancreatic carcinoma
  • Resistance
  • Targeted therapies
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles'. Together they form a unique fingerprint.

Cite this